Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: A Phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial

Clinical Therapeutics

Volumn 33, Issue 8, 2011, Pages 1057-1068

  Suh, Jung Won ^a,b   Seung, Ki Bae ^c   Gwak, Chung Hwan ^d   Kim, Kwon Sam ^e   Hong, Soon Jun ^f   Park, Tae Ho ^g   Kim, Sang Hyun ^h   Choi, Young Jin ⁱ   Joo, Seung Jea ^j   Tahk, Seung Jea ^k   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Gyeongsang National University   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f Korea University College of Medicine   (South Korea)

^g Dong A University College of Medicine   (South Korea)

^h Seoul National University   (South Korea)

ⁱ Hallym University   (South Korea)

^j Jeju National University   (South Korea)

^k Ajou University Medical Center   (South Korea)

more..

Author keywords

Asian; Aspirin; Clopidogrel bisulfate; Clopidogrel resinate; Efficacy; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; CLOPIDOGREL RESINATE; PURINERGIC P2Y12 RECEPTOR; RESIN; UNCLASSIFIED DRUG;

ADULT; AGED; APPENDICITIS; ARTICLE; BREAST DISEASE; CARDIAC PATIENT; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EAR DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; IMMUNOPATHOLOGY; INJURY; INNER EAR DISEASE; INTOXICATION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MIDDLE EAR DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; POINT OF CARE TESTING; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STABLE ANGINA PECTORIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 80051615049     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.07.001     Document Type: Article

References (37)

1. Wang T.H., Bhatt D.L., Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006, 27:647-654.
2. Becker R.C., Meade T.W., Berger P.B., et al. The primary and secondary prevention of coronary artery disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:776S-814S.
3. Neubauer H., Kruger J.C., Lask S., et al. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol 2009, 98:533-540.
4. Agawal H., Kaul N., Paradkar A.R., Mahadik K.R. Stability indicating HPTLC determination of clopidogrel bisulfate as bulk drug and in pharmaceutical dosage form. Talanta 2003, 61:581-589.
5. Gomez Y., Adams E., Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal 2004, 34:341-348.
6. Zhang Z.Y., Ping Q.N., Xiao B. Microencapsulation and characterization of tramadol-resin complexes. J Control Release 2000, 66:107-113.
7. Ki M.H., Choi M.H., Ahn K.B., et al. The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. Arch Pharm Res 2008, 31:250-258.
8. Kim S.D., Kang W., Lee H.W., et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther 2009, 31:793-803.
9. Akkaramongkolporn P., Terada K., Yonemochi E. Molecular properties of propranolol hydrochloride prepared as drug-resin complexes. Drug Dev Ind Pharm 2001, 27:359-364.
10. Pongjanyakul T., Priprem A., Chitropas P., Puttipipatkhachorn S. Effect of polysulfonate resins and direct compression fillers on multiple-unit sustained-release dextromethorphan resinate tablets. AAPS PharmSciTech 2005, 6:E190-E197.
11. Shepherd G., Klein-Schwartz W., Burstein A.H. Efficacy of the cation exchange resin, sodium polystyrene sulfonate, to decrease iron absorption. J Toxicol Clin Toxicol 2000, 38:389-394.
12. Braunlin W., Xu Q., Hook P., et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 2004, 87:534-539.
13. Rivard A.L., Raup S.M., Beilman G.J. Sodium polystyrene sulfonate used to reduce the potassium content of a high-protein enteral formula: a quantitative analysis. JPEN J Parenter Enteral Nutr 2004, 28:76-78.
14. Barker R.H., Dagher R., Davidson D.M., Marquis J.K. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther 2006, 24:1525-1534.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. Third Report of the National Cholesterol Education Program (NCEP).
16. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
17. ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045. World Medical Association Declaration of Helsinki.
18. King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation 2008, 117:261-295.
19. Neubauer H., Gunesdogan B., Hanefeld C., et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J 2003, 24:1744-1749.
20. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003, 107:32-37.
21. Angiolillo D.J., Capranzano P., Goto S., et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the Optimus-2 Study. Eur Heart J 2008, 29:2202-2211.
22. Malinin A., Pokov A., Spergling M., et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2y12(r) rapid analyzer: the Verify Thrombosis Risk Assessment (Veritas) study. Thromb Res 2007, 119:277-284.
23. Lindman H.R. Analysis of Variance in Complex Experimental Designs 1974, WH Freeman & Co, San Francisco, CA.
24. Hinkelmann K., Kempthorne O. Design and Analysis of Experiments, Volume I: Introduction to Experimental Design 2008, Wiley, New York, NY.
25. Mehran R., Brodie B., Cox D.A., et al. The harmonizing outcomes with revascularization and stents in acute myocardial infarction (horizons-ami) trial: Study design and rationale. Am Heart J 2008, 156:44-56.
26. Nikolsky E., Lansky A.J., Sudhir K., et al. Spirit IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009, 158:520-526. e522.
27. Paniccia R., Antonucci E., Gori A.M., et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007, 5:1839-1847.
28. Malinin A., Pokov A., Swaim L., et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006, 28:315-322.
29. Karon B.S., Wockenfus A., Scott R., et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin Chem 2008, 54:1060-1065.
30. Gremmel T., Steiner S., Seidinger D., et al. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 2010, 8:37-42.
31. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242.
32. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762.
33. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000.
34. Park S.H., Kim W., Park C.S., et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009, 104:1292-1295.
35. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
36. Desai N.R., Mega J.L., Jiang S., et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009, 53:1273-1278.
37. Angiolillo D.J., Capranzano P., Desai B., et al. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res 2009, 124:318-322.